No Data
Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients With Lower Plasma P-tau217 Correlated With Improvements in Key Indicators of Alzheimer's Disease Biology
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Express News | Cognition Therapeutics’ Analysis Correlates Biomarker Changes With Cognitive Benefit in Alzheimer’s Population
Cognition Therapeutics' Analysis Correlates Biomarker Changes With Cognitive Benefit in Alzheimer's Population
Cognition Therapeutics | 10-Q: Q3 2024 Earnings Report
Cognition Therapeutics | 8-K: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Jason Crawford596 : I bought at .49 pre and sitting down 10c waiting for something ,even flat would be better than this